Immix Biopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| IMMX | INBX | VRXA | MBX | ZBIO | IMNM | |
|---|---|---|---|---|---|---|
| Market cap | 766.85M | 1.33B | 161.20M | 2.51B | 1.72B | 2.26B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -10.9 | -10.3 | — | -13.1 | -5.7 | -7.9 |
| Price/book | 2.9 | -25.1 | -0.9 | 6.1 | 6.8 | 4.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +278.40% | +176.35% | −87.97% | +267.17% | +2.71% | +37.19% |
| Today | −2.22% | −4.72% | −9.52% | −2.29% | −3.15% | −2.05% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All IMMX news ›Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference
Investing News Network Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in AL Amyloidosis, today announced that it…
Immatics N.V. (NASDAQ:IMTX) Stock Has Consensus Target Price of $20.60 According to Brokerages
View Our Latest Stock Report on Immatics Shares of IMTX stock opened at $7.43 on Friday. The firm has a market cap of $1.02 billion, a P/E ratio of -3.99 and a beta of 1.36. Immatics has a 1-year low of $7.02 and a 1-year high of $12.41.…
Immunome (NASDAQ:IMNM) Stock Price Down 6.6% – What’s Next?
Posted by Michael Walen on Oct 8th, 2026 Immunome, Inc. (NASDAQ:IMNM – Get Free Report) shares dropped 6.6% during mid-day trading on Tuesday. The company traded as low as $19.84 and last traded at $19.7820. Approximately 448,182 shares…
Immatics (NASDAQ:IMTX) Sets New 52-Week Low - Here's What Happened
Immatics N.V. (NASDAQ:IMTX - Get Free Report)'s share price reached a new 52-week low on Saturday. The company traded as low as $7.40 and last traded at $7.59, with a volume of 1256460 shares. The stock had previously closed at $8.44. Get…
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
– Financing includes leading U.S. biotechnology institutional investors and mutual funds – Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes. J.P. Morgan…
Immix Biopharma (NASDAQ:IMMX) Sees Strong Trading Volume on Analyst Upgrade
Posted by Mitch Edgeman on Oct 1st, 2026 Read Our Latest Stock Analysis on Immix Biopharma The firm has a market cap of $744.02 million, a P/E ratio of -11.82 and a beta of 0.20. The firm’s 50-day simple moving average is $11.66 and its…
Immix Biopharma Closes $117.1 Million Underwritten Registered Offering | IMMX Stock News
Immix Biopharma raised $117.1 million from a stock offering to fund NXC-201 development and corporate purposes. The public offering price for Immix Biopharma's shares was $11.00 per share. Immix Biopharma generated approximately $117.1…
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript
Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call September 29, 2026 8:00 AM EDTCompany ParticipantsIlya Rachman - Co-Founder, CEO, Chief Scientific...
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Immix Biopharma (IMMX) was in focus on Tuesday as BofA grew more confident in the prospects for its lead CAR-T therapy, NXC-201, following encouraging new clinical data in a rare disease characterized by harmful protein buildup in organs.…
Immix Biopharma prices $125M stock offering (IMMX:NASDAQ)
Immix Biopharma (IMMX) prices 11.36M-share offering at $11 to raise $125M to fund NXC-201 development.
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
themarketsdaily.com3
-
investingnews.com2
-
marketbeat.com2
-
quiverquant.com2
-
seekingalpha.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.